New tool aims to help men decide when to cut back on prostate cancer testing
NCT ID NCT05497024
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is developing and testing an educational tool to help men aged 65 and older with prostate cancer decide with their doctors whether to reduce the frequency of follow-up tests like biopsies. The tool is being tested with 45 participants, including patients, caregivers, and clinicians, to see if it is easy to use and helpful. The goal is to support shared decision-making for men whose cancer is unlikely to progress or who may no longer need aggressive monitoring.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a practical decision aid that helps men and their doctors make more informed choices about reducing unnecessary tests.
- What could go wrong
- This is a small, early-stage usability study with only 45 participants, so the tool may not work well for everyone or in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 45 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2022
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
M D Anderson Cancer Center
- Ages
-
65 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Patients Inclusion Criteria: 1. Males aged 65 or older 2. Diagnosis of localized prostate cancer 3. On active surveillance for 12 or more months 4. Fluent in English Exclusion Criteria: 1\. Receiving treatment for another cancer (primary or recurrence) Caregivers Inclusion Criteria: 1. Aged 18 or older 2. Fluent in English 3. Involved with the care of an eligible patient (i.e. partner, close friend, family member, companion) Exclusion Criteria: 4. None Clinicians Inclusion Criteria: 1. Aged 18 or older 2. Fluent in English 3. Provides clinical care for patients with prostate cancer (e.g. medical oncologists, urologists, radiation oncologists, nurse practitioners, physician assistants) Exclusion Criteria: 1\. None
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Localized prostate cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A scanner in the operating room could show surgeons exactly where prostate cancer remains
- New PET tracer aims to light up hidden cancer targets
- Can daily adaptive radiotherapy spare healthy tissue in prostate cancer?
- Can a radioactive tracer and MRI reveal prostate Cancer's true extent?
- Light-Based imaging aims to spot prostate cancer left behind after surgery
- Five-Fraction radiation plus hormone therapy tested against High-Risk prostate cancer